(1S,2R,8S,9S,10S,13S,14S,17S)-17-Diethylcarbamoyl-10,13-dimethyl-3-oxo-2,3,7,8,9,10,11,12,13,14,15,16,17,20-tetradecahydro-1H-6-aza-cyclopropa[1,2]cyclopenta[a]phenanthrene-6-carboxylic acid tert-butyl ester | 157724-29-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (1S,2R,8S,9S,10S,13S,14S,17S)-17-Diethylcarbamoyl-10,13-dimethyl-3-oxo-2,3,7,8,9,10,11,12,13,14,15,16,17,20-tetradecahydro-1H-6-aza-cyclopropa[1,2]cyclopenta[a]phenanthrene-6-carboxylic acid tert-butyl ester
• 英文别名: tert-butyl (1S,2S,3S,5R,11S,12S,15S,16S)-15-(diethylcarbamoyl)-2,16-dimethyl-6-oxo-9-azapentacyclo[9.7.0.02,8.03,5.012,16]octadec-7-ene-9-carboxylate
• CAS: 157724-29-3
• 化学式: C₂₉H₄₄N₂O₄
• 分子量: 484.679
• InChiKey: MRMGOKPMEFCPAN-GSVZAIQCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  35
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  66.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (1S,2R,8S,9S,10S,13S,14S,17S)-17-Diethylcarbamoyl-10,13-dimethyl-3-oxo-2,3,7,8,9,10,11,12,13,14,15,16,17,20-tetradecahydro-1H-6-aza-cyclopropa[1,2]cyclopenta[a]phenanthrene-6-carboxylic acid tert-butyl ester 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 以57%的产率得到17β-(N,N-diethylcarbamoyl)-1α,2α-methano-6-azaandrost-4-en-3-one
  参考文献：
  名称：

  6-Azasteroids: Structure-Activity Relationships for Inhibition of Type 1 and 2 Human 5.alpha.-Reductase and Human Adrenal 3.beta.-Hydroxy-.DELTA.5-steroid Dehydrogenase/3-Keto-.DELTA.5-steroid Isomerase

  摘要：

  6-Azaandrost-4-en-3-ones were synthesized and tested versus human type 1 and 2 steroid 5 alpha-reductase (5AR) and human adrenal 3 beta-hydroxy-Delta(5)-steroid dehydrogenase/3-keto-Delta(5)-steroid isomerase (3BHSD) to explore the structure-activity relationship of this novel series in order to optimize potency versus both isozymes of 5AR and selectivity versus 3BHSD. Compounds with picomolar IC50's versus human type 2 5AR and low nanomolar K-i's versus human type 1 5AR with 100-fold selectivity versus 3BHSD were identified (70). Preliminary in vivo evaluation of some optimal compounds from this series in a chronic castrated rat model of 5AR inhibitor-induced prostate involution and dog pharmacokinetic measurements identified a series of 17 beta-[N-(diphenylmethyl)carbamoyl]-6-azaandrost-4-en-3-ones (compounds 54, 66, and 67) with good in vivo efficacy and half-life in the dog. Inhibitors with, at the minimum, low nanomolar potency toward both human 5AR's and selectivity versus 3BHSD may show advantages over previously known 5AR inhibitors in the treatment of disease states which depend upon dihydrotestosterone, such as benign prostatic hyperplasia.

  DOI：

  10.1021/jm00041a014
• 作为产物：
  描述：

  (1S,3aS,3bS,9aR,9bS,11aS)-1-Chlorocarbonyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,7,9a,9b,10,11,11a-dodecahydro-cyclopenta[i]phenanthridine-5-carboxylic acid tert-butyl ester 在 sodium hydride 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 (1S,2R,8S,9S,10S,13S,14S,17S)-17-Diethylcarbamoyl-10,13-dimethyl-3-oxo-2,3,7,8,9,10,11,12,13,14,15,16,17,20-tetradecahydro-1H-6-aza-cyclopropa[1,2]cyclopenta[a]phenanthrene-6-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  6-Azasteroids: Structure-Activity Relationships for Inhibition of Type 1 and 2 Human 5.alpha.-Reductase and Human Adrenal 3.beta.-Hydroxy-.DELTA.5-steroid Dehydrogenase/3-Keto-.DELTA.5-steroid Isomerase

  摘要：

  6-Azaandrost-4-en-3-ones were synthesized and tested versus human type 1 and 2 steroid 5 alpha-reductase (5AR) and human adrenal 3 beta-hydroxy-Delta(5)-steroid dehydrogenase/3-keto-Delta(5)-steroid isomerase (3BHSD) to explore the structure-activity relationship of this novel series in order to optimize potency versus both isozymes of 5AR and selectivity versus 3BHSD. Compounds with picomolar IC50's versus human type 2 5AR and low nanomolar K-i's versus human type 1 5AR with 100-fold selectivity versus 3BHSD were identified (70). Preliminary in vivo evaluation of some optimal compounds from this series in a chronic castrated rat model of 5AR inhibitor-induced prostate involution and dog pharmacokinetic measurements identified a series of 17 beta-[N-(diphenylmethyl)carbamoyl]-6-azaandrost-4-en-3-ones (compounds 54, 66, and 67) with good in vivo efficacy and half-life in the dog. Inhibitors with, at the minimum, low nanomolar potency toward both human 5AR's and selectivity versus 3BHSD may show advantages over previously known 5AR inhibitors in the treatment of disease states which depend upon dihydrotestosterone, such as benign prostatic hyperplasia.

  DOI：

  10.1021/jm00041a014

文献信息

• 6-Azasteroids: Structure-Activity Relationships for Inhibition of Type 1 and 2 Human 5.alpha.-Reductase and Human Adrenal 3.beta.-Hydroxy-.DELTA.5-steroid Dehydrogenase/3-Keto-.DELTA.5-steroid Isomerase
  作者：Stephen V. Frye、Curt D. Haffner、Patrick R. Maloney、Robert A. Mook、George F. Dorsey、Roger N. Hiner、Cindy M. Cribbs、Thomas N. Wheeler、John A. Ray

  DOI：10.1021/jm00041a014

  日期：1994.7

  6-Azaandrost-4-en-3-ones were synthesized and tested versus human type 1 and 2 steroid 5 alpha-reductase (5AR) and human adrenal 3 beta-hydroxy-Delta(5)-steroid dehydrogenase/3-keto-Delta(5)-steroid isomerase (3BHSD) to explore the structure-activity relationship of this novel series in order to optimize potency versus both isozymes of 5AR and selectivity versus 3BHSD. Compounds with picomolar IC50's versus human type 2 5AR and low nanomolar K-i's versus human type 1 5AR with 100-fold selectivity versus 3BHSD were identified (70). Preliminary in vivo evaluation of some optimal compounds from this series in a chronic castrated rat model of 5AR inhibitor-induced prostate involution and dog pharmacokinetic measurements identified a series of 17 beta-[N-(diphenylmethyl)carbamoyl]-6-azaandrost-4-en-3-ones (compounds 54, 66, and 67) with good in vivo efficacy and half-life in the dog. Inhibitors with, at the minimum, low nanomolar potency toward both human 5AR's and selectivity versus 3BHSD may show advantages over previously known 5AR inhibitors in the treatment of disease states which depend upon dihydrotestosterone, such as benign prostatic hyperplasia.